Home > Resources > Whitepapers > Cell Biology and Cancer

Cell Biology and Cancer

January 18, 2019

We now understand a lot about cancer. We know that it results from a series of genetic changes having to do with cell division and growth control and genetic instability, mortality, the suicide mechanism in cells; the ability of the cells to migrate; the ability of the cells to attract them a blood supply. And so that’s pretty profound that in a few sentences one can summarize a sophisticated, fundamental understanding of what cancer is.

Spotlight

PolyActiva

PolyActiva is an Australian-based biotechnology company that has developed a platform technology to deliver drugs to specific sites in the body. The polymeric prodrugs can take various forms, including rod-shaped implants, injectable gels and topical films and the rate of drug delivery can be controlled for up to 12 months.

OTHER WHITEPAPERS

Optimizing Freeze-Thaw Processes for Cell and Gene Therapy Commercialization

whitePaper | June 23, 2022

Cell and gene therapies require both efficient and reliable freeze-thaw systems. Building the most effective system depends on selecting the right materials and instruments.

Valorization of Starch to Biobased Materials

whitePaper | May 30, 2022

Many concerns are being expressed about the biodegradability, biocompatibility, and longterm viability of polymer-based substances. This prompted the quest for an alternative source of material that could be utilized for various purposes.

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.

rFC adoption for bacterial endotoxin testing

whitePaper | December 7, 2022

OVER THE LAST 20 years, the worldwide value of traded pharmaceutical goods has grown six‑fold, from $113 billion in 2000 to $629 billion in 2019.1 Yet amid such robust growth comes risk to supply chain security as manufacturers become increasingly dependent on a global network of suppliers

Preparing Biologics for Commercialization

whitePaper | December 14, 2022

Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product.

Antibodies to Viral Vectors Responding to Demands toSimplify Progress in Bioprocessing

whitePaper | March 16, 2023

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Optimizing Freeze-Thaw Processes for Cell and Gene Therapy Commercialization

whitePaper | June 23, 2022

Cell and gene therapies require both efficient and reliable freeze-thaw systems. Building the most effective system depends on selecting the right materials and instruments.